WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Judge blocks Biden administration from enforcing new gun sales background check rule in Texas
These hilarious notices will make you do a double take
Auburn running back Brian Battie on ventilator after weekend shooting in Florida, coach says
Bichette has 4 hits, Berríos snaps 4
Who is Abi Carter? Inside the American Idol winner's unconventional family life
Seven sneaky clauses in estate agent contracts that can cost you dear
Colton Herta shows speed as Honda fights back in penultimate Indy 500 practice session
Benedict Cumberbatch looks suave as he joins his co
Climber found dead on Denali, North America's tallest peak
Colton Herta shows speed as Honda fights back in penultimate Indy 500 practice session
BBC Countryfile star Adam Henson's wife wrote heartbreaking goodbye letters after cancer diagnosis